Q4 2017 Earnings Estimate for Urogen Pharma (URGN) Issued By Jefferies Group
Urogen Pharma (NASDAQ:URGN) – Stock analysts at Jefferies Group reduced their Q4 2017 earnings per share estimates for shares of Urogen Pharma in a report issued on Wednesday. Jefferies Group analyst M. Andrews now anticipates that the company will post earnings per share of ($0.67) for the quarter, down from their prior estimate of ($0.64). Jefferies Group currently has a “Buy” rating and a $37.00 price target on the stock. Jefferies Group also issued estimates for Urogen Pharma’s FY2018 earnings at ($2.47) EPS, FY2019 earnings at ($2.59) EPS and FY2020 earnings at ($1.47) EPS.
Several other analysts have also issued reports on URGN. Cowen and Company reaffirmed a “buy” rating on shares of Urogen Pharma in a research report on Wednesday. UBS AG lowered shares of Urogen Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday. CIBC reaffirmed an “outperform” rating and set a $51.00 price target (up from $32.00) on shares of Urogen Pharma in a research report on Wednesday. Oppenheimer Holdings, Inc. set a $32.00 price target on shares of Urogen Pharma and gave the stock a “buy” rating in a research report on Monday, August 14th. Finally, Zacks Investment Research lowered shares of Urogen Pharma from a “buy” rating to a “hold” rating in a research report on Friday, August 18th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $36.80.
Urogen Pharma (NASDAQ URGN) traded up $0.75 during midday trading on Friday, reaching $41.00. 176,311 shares of the company’s stock traded hands, compared to its average volume of 62,480. Urogen Pharma has a 1 year low of $13.01 and a 1 year high of $44.63.
Several hedge funds have recently added to or reduced their stakes in the stock. Spark Investment Management LLC acquired a new stake in Urogen Pharma during the second quarter worth about $856,000. Menora Mivtachim Holdings LTD. acquired a new stake in Urogen Pharma during the second quarter worth about $2,331,000. LLBH Private Wealth Management LLC acquired a new stake in Urogen Pharma during the second quarter worth about $695,000. Alps Advisors Inc. acquired a new stake in Urogen Pharma during the second quarter worth about $195,000. Finally, Jennison Associates LLC acquired a new stake in Urogen Pharma during the second quarter worth about $3,168,000. Institutional investors and hedge funds own 40.55% of the company’s stock.
Urogen Pharma Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.